Revolution Medicines RVMD 深 沪
等待开盘 10-29 09:30:00 美东时间
188.72
+2.500
+1.34%
华盛通- 最 高188.85
- 今 开185.08
- 成交量 89.04万股
- 最 低 183.855
- 昨 收 186.22
- 总市值 404.50亿
- 52周最高 224.31
- 市盈率 静 --
- 换手率 0.42%
- 52周最低 61.50
- 委 比 2.44%
- 总股本 2.14亿
- 历史最高 224.31
- 量 比 0.56
- 振 幅 2.68%
- 历史最低 14.08
- 每 手 1
- 风险率 49.70%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Jim Cramer: This Tech Stock ‘Sells At A Low Multiple’
On CNBC’s “Mad Money Lightning Round,” Jim Cramer said Penguin Solutions, Inc. (NASDAQ:PENG) “sells at a low multiple, and I don’t mind a low-multiple tech stock because they tend not to get hurt as much as the others.” On the earnings front, Penguin Solutions reported better-than-expected fourth-qu...
10-28 19:59
Revolution Medicines to Participate in November 2026 Investor Conferences
Revolution Medicines, Inc. (Nasdaq: RVMD), a global oncology company focused on treating RAS-addicted cancers, announced that its CEO, Mark A. Goldsmith, M.D., Ph.D., will participate in two investor conferences: the 3rd Annual Guggenheim Healthcare Innovation Conference on November 10 at 8:30 a.m. ET and the Jefferies Global Healthcare Conference in London on November 16 at 5:30 a.m. ET. Webcasts and replays of these events will be available on ...
10-27 20:05
治疗“癌症之王”，明星RAS抑制剂组合再传捷报！
在今年的美国临床肿瘤学会（ASCO）年会上，Revolution Medicines开发的RAS抑制剂daraxonrasib凭借3期临床试验的积极结果，赢得全...
10-26 18:01
Revolution Medicines收跌0.37%，成交额3.22亿美元
10月24日，Revolution Medicines（RVMD）收跌0.37%，报186.99美元，成交额3.22亿美元，市值400.79亿美元。 行情数据...
10-24 04:39
Why Is Tango Therapeutics Stock Trading Lower After Cancer Drug Data?
Tango Therapeutics Inc. (NASDAQ:TNGX) on Friday shared Phase 1/2 trial data for its investigational drug vopimetostat, revealing strong efficacy in treating advanced pancreatic and lung cancers. The biotechnology firm reported marked tumor shrinkage when combining the PRMT5 inhibitor with Revolution...
10-23 23:36
美债收益率走高，生物科技股遇冷：临床突破之外，现金储备正决定谁能活到商业化
由于国债收益率的快速上升削弱了生物技术公司股票的吸引力，投资者开始对生物技术股票持谨慎态度。这些公司通常被视为对突破性医疗疗法孤注一掷且风险极高的投资。
10-22 21:56
TD Cowen Reiterates Buy on Revolution Medicines, Announces $250 Price Target
TD Cowen analyst Tyler Van Buren reiterates Revolution Medicines (NASDAQ:RVMD) with a Buy and announces $250 price target.
10-21 23:10
Revolution Medicines Begins Phase 3 Trial For Advanced Lung Cancer Treatment
Revolution Medicines Inc. (NASDAQ:RVMD) began treating patients in its global Phase 3 clinical study, RASolve 308, to evaluate a combination treatment for metastatic lung cancer. The trial tests the company’s investigational therapy, zoldonrasib, alongside standard care as a first-line treatment for...
10-21 01:00
Revolution Medicines Inc(RVMD)股票10月20日盘中上涨7.41%：真相来了
• Revolution Medicines已在新的全球3期临床试验中启动患者给药治疗。 • 分析师发布看涨研报并上调了该公司目标价。 • 该公司报告全年营收为零，净亏损达11.3亿美元。
10-20 18:16
美股大行评级 | 潜在涨幅523.44%！HC Wainwright & Co.上调Annexon目标价至25美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Annexon"买入"评级，目标价从14美元升至25美元；HC Wainwright & Co.：维持Alto Neuroscience"买入"评级，目标价从55美元升至60美元
10-20 12:36
